Primary breast lymphoma : patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study

Autor: Yazid Belkacemi, Pauline Gastelblum, Tan Nguyen, Philip Poortmans, René-Olivier Mirimanoff, Rita Abi Raad, Wendy Jeanneret-Sozzi, Daniel R. Zwahlen, Beat Amsler, Marco Krengli, Philippe Maingon, Mahmut Ozsahin, Alphonse G. Taghian, Sylviane Villette, Ron Epelbaum, Cristina Gutierrez, Pierre Scalliet
Přispěvatelé: UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Service de radiothérapie oncologique
Jazyk: angličtina
Rok vydání: 2008
Předmět:
Oncology
Male
Cancer Research
Lymphoma
medicine.medical_treatment
Breast Neoplasms - mortality
therapy
Outcome (game theory)
Breast cancer
Surgical oncology
Mastectomy
Aged
80 and over
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Prognosis
Combined Modality Therapy
Treatment Outcome
Female
Cancer chemotherapy
Biologie
Antineoplastic Agents - therapeutic use
Breast Neoplasms
Male - mortality
therapy
Research Article
Adult
medicine.medical_specialty
Lymphoma - mortality
therapy
Radioteràpia
Antineoplastic Agents
Breast Neoplasms
lcsh:RC254-282
Breast Neoplasms
Male
Càncer de mama
Quimioteràpia del càncer
Primary Breast Lymphoma
Internal medicine
Genetics
medicine
Mastectomia
Humans
Aged
Neoplasm Recurrence
Local
Radiotherapy
Retrospective Studies
Survival Analysis
Survival analysis
business.industry
Retrospective cohort study
Surgery
Cancérologie
Radiation therapy
business
Zdroj: BMC Cancer, Vol. 8, p. 86 (2008)
BMC cancer, 8
BMC Cancer, Vol 8, Iss 1, p 86 (2008)
Dipòsit Digital de la UB
Universidad de Barcelona
BMC Cancer
BMC Cancer, vol. 8, no. 86, pp. 86
Popis: Background: To asses the clinical profile, treatment outcome and prognostic factors in primary breast lymphoma (PBL). Methods: Between 1970 and 2000, 84 consecutive patients with PBL were treated in 20 institutions of the Rare Cancer Network. Forty-six patients had Ann Arbor stage IE, 33 stage IIE, 1 stage IIIE, 2 stage IVE and 2 an unknown stage. Twenty-one underwent a mastectomy, 39 conservative surgery and 23 biopsy; 51 received radiotherapy (RT) with (n = 37) or without (n = 14) chemotherapy. Median RT dose was 40 Gy (range 12-55 Gy). Results: Ten (12%) patients progressed locally and 43(55%) had a systemic relapse. Central nervous system (CNS) was the site of relapse in 12 (14%) cases. The 5-yr overall survival, lymphoma-specific survival, disease-free survival and local control rates were 53%, 59%, 41% and 87% respectively. In the univariate analyses, favorable prognostic factors were early stage, conservative surgery, RT administration and combined modality treatment. Multivariate analysis showed that early stage and the use of RT were favorable prognostic factors. Conclusion: The outcome of PBL is fair. Local control is excellent with RT or combined modality treatment but systemic relapses, including that in the CNS, occurs frequently. © 2008 Jeanneret-Sozzi et al; licensee BioMed Central Ltd.
SCOPUS: ar.j
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz: